Static Magnetic Field Exposure Reproduces Cellular Effects of the Parkinson's Disease Drug Candidate ZM241385

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Wang, Zhiyun ^a   Che, Pao Lin ^a   Du, Jian ^a   Ha, Barbara ^a   Yarema, Kevin J ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYCLIC AMP; IRON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; 2 (4 (2 CARBOXYETHYL)PHENETHYLAMINO) 5' N ETHYLCARBOXAMIDOADENOSINE; 2-(4-(2-CARBOXYETHYL)PHENETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; CALCIUM; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DRUG RESPONSE; ENZYME PHOSPHORYLATION; IRON TRANSPORT; MAGNETIC FIELD; MAGNETOTHERAPY; NERVE FIBER GROWTH; NONHUMAN; PARKINSON DISEASE; RAT; THERAPY EFFECT; ANALYSIS OF VARIANCE; ANIMAL; DRUG EFFECT; MAGNETISM; METABOLISM; METHODOLOGY; NEURITE; PHOSPHORYLATION; WESTERN BLOTTING;

RATTUS;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALCIUM; CELL PROLIFERATION; CYCLIC AMP; IRON; MAGNETIC FIELD THERAPY; MAGNETICS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEURITES; PARKINSON DISEASE; PC12 CELLS; PHENETHYLAMINES; PHOSPHORYLATION; RATS; RECEPTOR, ADENOSINE A2A; TRIAZINES; TRIAZOLES;

EID: 78249278163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013883     Document Type: Article

References (81)

1. Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A, et al. (2009) Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15: S35-S38.
2. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, et al. (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17: 729-762.
3. 2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol 217: 231-234.
4. Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8: 67-81.
5. Azanza MJ (1989) Steady magnetic fields mimic the effect of caffeine on neurons. Brain Res 489: 195-198.
6. Sandyk R, Anninos PA, Tsagas N, Derpapas K (1992) Magnetic fields in the treatment of Parkinson's disease. Int J Neurosci 63: 141-150.
7. Arendash GW, Sanchez-Ramos J, Mori T, Mamcarz M, Lin X, et al. (2010) Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. J Alzheimers Dis 19: 191-210.
8. Wang Z, Sarje A, Che P-L, Yarema KJ (2009) Moderate strength (0.23-0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells. BMC Genomics 10: 356.
9. Biber K, Lubrich B, Fiebich BL, Boddeke HW, van Calker D (2001) Interleukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. Neuropsychopharmacology 24: 86-96.
10. Olah ME, Stiles GL (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35: 581-606.
11. Theodosis DT, Bonhomme R, Vitiello S, Rougon G, Poulain DA (1999) Cell surface expression of polysialic acid on NCAM is a prerequisite for activitydependentmorphological neuronal and glial plasticity. J Neurosci 19: 10228-10236.
12. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73: 2424-2428.
13. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM (2000) Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 283: 193-196.
14. Meng H, Li C, Feng L, Cheng B, Wu F, et al. (2007) Effects of Ginkgolide B on 6-OHDA-induced apoptosis and calcium over load in cultured PC12. Int J Dev Neurosci 25: 509-514.
15. 2A receptor. J Physiol 508: 95-107.
16. Ferre S, O'Connor WT, Fuxe K, Ungerstedt U (1993) The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13: 5402-5406.
17. Beitner-Johnson D, Leibold J, Millhorn DE (1998) Hypoxia regulates the cAMPand Ca2+ /calmodulin signaling systems in PC12 cells. Biochem Biophys Res Commun 242: 61-66.
18. 2A receptor-mediated inhibition of calcium current in rat PC12 cells via downregulation of protein kinase A. J Physiol 512: 351-363.
19. 2A receptors in PC12 cells and increases receptor-mediated formation of cAMP. Naunyn Schmiedebergs Arch Pharmacol 365: 150-157.
20. Vajanaphanich M, Schultz C, Tsien RY, Traynor-Kaplan AE, Pandol SJ, et al. (1995) Cross-talk between calcium and cAMP-dependent intracellular signaling pathways. Implications for synergistic secretion in T84 colonic epithelial cells and rat pancreatic acinar cells. J Clin Invest 96: 386-393.
21. Tenuzzo B, Chionna A, Panzarini E, Lanubile R, Tarantino P, et al. (2006) Biological effects of 6 mT static magnetic fields: A comparative study in different cell types. Bioelectromagnetics 27: 560-577.
22. 2A adenosine receptor in PC12 cells. J Neurochem 71: 1251-1260.
23. 2A adenosine receptor agonist. Life Sci 76: 367-377.
24. 2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. Cell Struct Funct 29: 101-110.
25. 2A selective adenosine receptor antagonist. Br J Pharmacol 115: 1096-1102.
26. 2A receptor antagonists. J Med Chem 47: 4291-4299.
27. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP (2000) Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 275: 18195-18200.
28. Kobayashi S, Zimmermann H, Millhorn DE (2000) Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J Neurochem 74: 621-632.
29. Jang JH, Surh YJ (2005) AP-1 mediates b-amyloid-induced iNOS expression in PC12 cells via the ERK2 and p38 MAPK signaling pathways. Biochem Biophys Res Commun 331: 1421-1428.
30. 2A receptors upon NGF-induced differentiation of PC12 cells. Neuropharmacology 36: 1319-1326.
31. Zhang L, Dawson VL, Dawson TM (2006) Role of nitric oxide in Parkinson's disease. Pharmacol Ther 109: 33-41.
32. Narkar VA, Hussain T, Pedemonte C, Lokhandwala MF (2001) Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells. J Am Soc Nephrol 12: 1844-1852.
33. Tenuzzo B, Vergallo C, Dini L (2009) Effect of 6 mT static magnetic field on the bcl-2, bax, p53 and hsp70 expression in freshly isolated and in vitro aged human lymphocytes. Tiss Cell 41: 169-179.
34. 2A receptors. Neuroscience 131: 321-329.
35. 2A receptors and via cAMP and MAPK signaling pathways. Biochem Biophys Res Commun 304: 795-800.
36. 2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. J Biol Chem 277: 33930-33942.
37. Wright TL, Brissot P, Ma WL, Weisiger RA (1986) Characterization of nontransferrin- bound iron clearance by rat liver. J Biol Chem 261: 10909-10914.
38. Sturrock A, Alexander J, Lamb J, Craven CM, Kaplan J (1990) Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem 265: 3139-3145.
39. Mwanjewe J, Martinez R, Agrawal P, Samson SE, Coughlin MD, et al. (2000) On the Ca2+ dependence of non-transferrin-bound iron uptake in PC12 cells. J Biol Chem 275: 33512-33515.
40. Mwanjewe J, Grover AK (2004) Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells. Biochem J 378: 975-982.
41. Schonfeld E, Yasharel I, Yavin E, Brand A (2007) Docosahexaenoic acid enhances iron uptake by modulating iron transporters and accelerates apoptotic death in PC12 cells. Neurochem Res 32: 1673-1684.
42. Gatto EM, Riobo N, Carreras MC, Poderoso JJ, Micheli FE (2002) Neuroprotection in Parkinson's disease; a commentary. Neurotoxic Res 4: 141-145.
43. LeWitt PA (2008) Levodopa for the treatment of Parkinson's disease. New Engl J Med 359: 2468-2476.
44. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ (2002) A metaanalysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52: 276-284.
45. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28: 1281-1291.
46. Mally J, Stone TW (1994) The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 46: 515-517.
47. Moreau JL, Huber G (1999) Central adenosine A(2A) receptors: an overview. Brain Res Rev 31: 65-82.
48. 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9: 2857-2860.
49. Pilla AA, Markov MS (1994) Bioeffects of weak electromagnetic fields. Rev Environ Health 10: 155-169.
50. McKay JC, Prato FS, Thomas AW (2007) A literature review: the effects of magnetic field exposure on blood flow and blood vessels in the microvasculature. Bioelectromagnetics 28: 81-98.
51. Taniguchi N, Kanai S, Kawamoto M, Endo H, Higashino H (2004) Study on application of static magnetic field for adjuvant arthritis rats. Evid Based Complement Alternat Med 1: 187-191.
52. Morris CE, Skalak TC (2007) Chronic static magnetic field exposure alters microvessel enlargement resulting from surgical intervention. J Appl Physiol 103: 629-636.
53. Colbert AP, Wahbeh H, Harling N, Connelly E, Schiffke HC, et al. (2009) Static magnetic field therapy: a critical review of treatment parameters. Evid Based Complement Alternat Med 6: 133-139.
54. 2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus. Br J Pharmacol 122: 1279-1284.
55. 2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
56. 2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 375: 133-144.
57. Nuccitelli S, Cerella C, Cordisco S, Albertini MC, Accorsi A, et al. (2006) Hyperpolarization of plasma membrane of tumor cells sensitive to antiapoptotic effects of magnetic fields. Ann New York Acad Sci 1090: 217-225.
58. De Nicola M, Cordisco S, Cerella C, Albertini MC, D'Alessio M, et al. (2006) Magnetic fields protect from apoptosis via redox alteration. Ann New York Acad Sci 1090: 59-68.
59. Rosen AD (2003) Mechanism of action of moderate-intensity static magnetic fields on biological systems. Cell Biochem Biophys 39: 163-173.
60. Braganza LF, Blott BH, Coe TJ, Melville D (1984) The superdiamagnetic effect of magnetic fields on one and two component multilamellar liposomes. Biochim Biophys Acta 801: 66-75.
61. Rosen AD (2003) Effect of 125 mT static magnetic field on the kinetics of voltage activated Na + channels in GH3 cells. Bioelectromagnetics 24: 517-523.
62. 2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. Cardiovasc Res 72: 292-302.
63. Wyatt AW, Steinart JR, Wheeler-Jones CP, Morgan AJ, Sugden D, et al. (2002) Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J 16: 1584-1594.
64. 2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes Glia 43: 190-194.
65. 2A receptors in Huntington's disease. Prog Neurobiol 81: 81.
66. Takahashi RN, Pamplona FA, Prediger RDS (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13: 2614-2632.
67. Engström S, Markov MS, McLean MJ, Holcomb RR, Markov JM (2002) Effects of non-uniform static magnetic fields on the rate of myosin phosphorylation. Bioelectromagnetics 23: 475-479.
68. Okano H, Onmori R, Tomita N, Ikada Y (2006) Effects of a moderate-intensity static magnetic field on VEGF-A stimulated endothelial capillary tubule formation in vitro. Bioelectromagnetics 27: 628-640.
69. Okano H, Tomita N, Ikada Y (2007) Effects of 120 mT static magnetic field on TGF-b1-inhibited endothelial tubular formation in vitro. Bioelectromagnetics 28: 497-499.
70. Okano H, Tomita N, Ikada Y (2008) Spatial gradient effects of 120 mT static magnetic field on endothelial tubular formation in vitro. Bioelectromagnetics 29: 233-236.
71. Rozen S, Skalesky HJ (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press. pp 365-386.
72. Wang Z, Sun Z, Li AV, Yarema KJ (2006) Roles for GNE outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation and apoptosis, and ERK1/2 phosphorylation. J Biol Chem 281: 27016-27028.
73. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 25: 402-408.
74. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, et al. (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177-33184.
75. Strehler BL (1974) Adenosine-59-triphosphate and creatine phosphate determination with luciferase. In: Bergemeyer HU, ed. Methods of Enzyme Analysis. New York, New York: Academic Press. pp 2112-2113.
76. Zhang Y, Geiger JD, Lautt WW (1991) Improved high-pressure liquid chromatographic-fluorometric assay for measurement of adenosine in plasma. Am J Physiol 260: G658-G664.
77. Tracey WR, Linden J, Peach MJ, Johns RA (1990) Comparison of spectrophotometric and biological assays for nitric oxide (NO) and endothelium- derived relaxing factor (EDRF): nonspecificity of the diazotization reaction for NO and failure to detect EDRF. J Pharmacol Exp Ther 252: 922-928.
78. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331: 370-375.
79. Petrov E, Martinac B (2007) Modulation of channel activity and gadolinium block of MscL by static magnetic fields. Eur Biophys J 36: 95-105.
80. Triantafilou M, Morath S, Mackie A, Hartung T, Triantafilou K (2004) Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J Cell Sci 17: 4007-4014.
81. Zhang X, Min X, Yang F (1998) Conformational basis of the phospholipid requirement for the activity of SR Ca2+ -ATPase. Chem Phys Lipids 97: 55-64.